December 29, 2011 — Navitoclax, a novel BH3 mimetic that blocks the function of BCL-2, has shown significant antileukemic activity in patients with chronic lymphocytic leukemia (CLL) in a phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results